These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Ijichi H; Chytil A; Gorska AE; Aakre ME; Bierie B; Tada M; Mohri D; Miyabayashi K; Asaoka Y; Maeda S; Ikenoue T; Tateishi K; Wright CV; Koike K; Omata M; Moses HL J Clin Invest; 2011 Oct; 121(10):4106-17. PubMed ID: 21926469 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Nagathihalli NS; Castellanos JA; VanSaun MN; Dai X; Ambrose M; Guo Q; Xiong Y; Merchant NB Oncotarget; 2016 Oct; 7(40):65982-65992. PubMed ID: 27602757 [TBL] [Abstract][Full Text] [Related]
6. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. Addison CL; Belperio JA; Burdick MD; Strieter RM BMC Cancer; 2004 Jun; 4():28. PubMed ID: 15214968 [TBL] [Abstract][Full Text] [Related]
8. Targeting both tumour-associated CXCR2 Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437 [TBL] [Abstract][Full Text] [Related]
9. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Matsuo Y; Raimondo M; Woodward TA; Wallace MB; Gill KR; Tong Z; Burdick MD; Yang Z; Strieter RM; Hoffman RM; Guha S Int J Cancer; 2009 Sep; 125(5):1027-37. PubMed ID: 19431209 [TBL] [Abstract][Full Text] [Related]
10. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells. Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041 [TBL] [Abstract][Full Text] [Related]
11. Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. Perusina Lanfranca M; Zhang Y; Girgis A; Kasselman S; Lazarus J; Kryczek I; Delrosario L; Rhim A; Koneva L; Sartor M; Sun L; Halbrook C; Nathan H; Shi J; Crawford HC; Pasca di Magliano M; Zou W; Frankel TL Gastroenterology; 2020 Apr; 158(5):1417-1432.e11. PubMed ID: 31843590 [TBL] [Abstract][Full Text] [Related]
12. Chemokine homeostasis vs. chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Zarbock A; Bishop J; Müller H; Schmolke M; Buschmann K; Van Aken H; Singbartl K Am J Physiol Lung Cell Mol Physiol; 2010 Mar; 298(3):L462-71. PubMed ID: 20061440 [TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of CXCR2 expression in pancreatic ductal carcinoma]. Wang Q; Zheng J; Ni Q; Zhu H; Lu Y; Qian H; Zhu J Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(48):3805-8. PubMed ID: 25623310 [TBL] [Abstract][Full Text] [Related]
14. Tumor-neuroglia interaction promotes pancreatic cancer metastasis. Su D; Guo X; Huang L; Ye H; Li Z; Lin L; Chen R; Zhou Q Theranostics; 2020; 10(11):5029-5047. PubMed ID: 32308766 [No Abstract] [Full Text] [Related]
15. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066 [TBL] [Abstract][Full Text] [Related]
16. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling. Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862 [TBL] [Abstract][Full Text] [Related]
17. Identification of ANXA1 as a lymphatic metastasis and poor prognostic factor in pancreatic ductal adenocarcinoma. Liu QH; Shi ML; Bai J; Zheng JN Asian Pac J Cancer Prev; 2015; 16(7):2719-24. PubMed ID: 25854353 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells. Fu S; Chen X; Lin HJ; Lin J Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433 [TBL] [Abstract][Full Text] [Related]
19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
20. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]